Denis Naughten (Roscommon-South Leitrim, Fine Gael)
Link to this: Individually | In context

Question 435: To ask the Minister for Health and Children if she will review the estimated cost of the full roll out of the human papilloma virus vaccine; if she has completed a cost benefit analysis of the vaccine programme; if she will reverse the decision not to roll out this vaccine programme; and if she will make a statement on the matter. [33277/09]

Pat Breen (Clare, Fine Gael)
Link to this: Individually | In context

Question 519: To ask the Minister for Health and Children her plans to roll-out the human Papilloma virus vaccine; and if she will make a statement on the matter. [33923/09]

Mary Harney (Dublin Mid West, Progressive Democrats)
Link to this: Individually | In context

I propose to take Questions Nos. 435 and 519 together.

I have considered all the relevant advice available to me in relation to the potential public health benefits of HPV vaccination in the prevention of cervical cancer and the wider policy implications for its possible introduction into the National Immunisation Programme. I accept the consensus view of the relevant expert bodies that the introduction of a universal high uptake vaccination programme in young girls, in conjunction with population based cervical screening, could significantly reduce overall cervical cancer incidence. All of the clinical advice available to me indicates that, in the context of the limited resources available, the national roll-out of a cervical screening programme should take precedence over the introduction of a HPV vaccination programme.

The Health Information and Quality Authority (HIQA) has completed an assessment of the cost effectiveness of HPV. It shows that the vaccine does have the potential to play an important long term role in the prevention of cervical cancer and that a vaccination programme should be put in place to enable these long term benefits to be realised.

Accordingly, in August 2008, the Health Service Executive (HSE) was requested by the Department to examine operational and procurement issues relating to the introduction of a HPV vaccination programme for 12 year old girls on a basis that would achieve maximum cost effectiveness and appropriate national uptake rates.

I am keeping the cost of implementing such a programme under review. I am committed to progressively introducing cancer prevention measures, such as new screening and vaccination programmes, according to clinical prioritisation within resources available.